Premium
Clinical perspective on apoptosis in the management of the BPH patient
Author(s) -
Fitzpatrick John
Publication year - 2000
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/1097-0045(2000)45:9+<47::aid-pros10>3.0.co;2-d
Subject(s) - terazosin , stromal cell , context (archaeology) , apoptosis , medicine , prostate , smooth muscle , alpha (finance) , cancer research , endocrinology , hyperplasia , biology , surgery , paleontology , biochemistry , construct validity , cancer , patient satisfaction
BACKGROUND Traditionally, α 1 ‐adrenoceptor (AR) antagonists have been assumed to produce clinical benefit by an exclusive action on the tone of the periurethral stromal smooth muscle. However, recent evidence has emerged of additional intra‐ and extraprostatic actions. METHODS This article attempts to put into clinical context the recently described effects of certain α 1 ‐AR on prostate cell dynamics (i.e., proliferation and apoptosis). RESULTS AND CONCLUSIONS There is good evidence that certain α 1 ‐AR antagonists, in addition to affecting stromal smooth muscle, have effects on prostatic apoptosis that contribute to the overall clinical profile. Furthermore, this is not a class effect and may be restricted to balanced quinazoline α blockers (BQABs), such as terazosin. Prostate Supplement 9:47–50, 2000. © 2000 Wiley‐Liss, Inc.